Definium Doses First Patient in Second Phase 3 Trial for Depression Drug

Event summary

  • Definium Therapeutics dosed the first patient in its Ascend Phase 3 trial for DT120 ODT in major depressive disorder (MDD).
  • The study will enroll 175 participants in the U.S. and evaluate efficacy and safety against placebo.
  • Ascend is the second Phase 3 trial for DT120 ODT, following the Emerge study expected to read out topline results in late Q2 2026.
  • DT120 ODT is a proprietary formulation of lysergide tartrate, using Catalent’s Zydis® ODT fast-dissolve technology.

The big picture

Definium’s Ascend trial is a critical step in validating DT120 ODT as a potential breakthrough in MDD treatment, an area plagued by high unmet needs and limited remission rates with existing therapies. The study’s design aligns with broader Phase 3 trials in generalized anxiety disorder (GAD), positioning Definium to potentially reshape the psychiatric treatment landscape. Success could position DT120 ODT as a differentiated option in a market desperate for faster-acting, more effective solutions.

What we're watching

Clinical Efficacy
Whether DT120 ODT can demonstrate meaningful differentiation in MDD treatment, addressing critical unmet needs.
Regulatory Pathway
The pace at which Definium can navigate FDA guidance and secure approval for psychedelic-inspired therapies.
Market Adoption
How quickly DT120 ODT could gain traction if proven effective, given the $326 billion annual economic burden of MDD in the U.S.

Related topics

Biotechnology